Newsroom
Stay up to date on the latest Legend news and information from Legend Biotech.
Stay up to date on the latest Legend news and information from Legend Biotech.
U.S. Food Drug Administration approved CARVYKTI™ (ciltacabtagene autoleucel;cilta-cel), a BCMA-directed CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody The CARTITUDE clinical development program is progressing to […]
Mar 18, 2022
CARVYKTI™ marks the first product approved by a health authority for Legend Biotech Approval is primarily based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with refractory or relapsed multiple myeloma after four or more prior lines of therapy including proteasome inhibitor, immunomodulatory agent […]
Feb 28, 2022
SOMERSET, N.J.—(BUSINESS WIRE) — February 18, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, […]
Feb 18, 2022
SOMERSET, NJ — (BUSINESS WIRE) — February 15, 2022 — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that on Friday, February 11, 2022, the company was informed by the U.S Food and Drug Administration (FDA) via email communication that its Phase 1 clinical […]
Feb 15, 2022
SOMERSET, N.J.— (BUSINESS WIRE) —February 11, 2022— Legend Biotech Corporation(NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen […]
Feb 11, 2022
Thank you for your interest in learning more about Legend Biotech.
media@legendbiotech.com
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.